NewAmsterdam Pharma Company has added more evidence that its CETP inhibitor obicetrapib is effective at lowering low-density lipoprotein cholesterol (LDL-C) in patients at risk of cardiovascular disease for whom existing therapies are insufficiently effective or tolerated. The results of the Phase III TANDEM trial combining the drug with ezetimibe generated optimism among analysts about the drug’s approvability and blockbuster sales potential.
NewAmsterdam’s Obicetrapib Boosts Approval Potential With Positive Combo Data
The company announced results of the TANDEM study combining the CETP inhibitor with ezetimibe, following successful monotherapy trial data announced in July
More from Clinical Trials
• By
The biotech is banking on itolizumab’s longer-term efficacy as well as unmet need in frontline acute graft-versus-host disease as it prepares to meet with the FDA.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.